Press Releases - 2023-01-06

Date	Title	Company
06-Jan-2023	Egnyte to provide early-stage life science startups a year of Egnyte’s platform at no cost	Egnyte
06-Jan-2023	PM Society Training Courses – Start 2023 with some fresh education and personal development	PM Society
06-Jan-2023	atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression	atai Life Sciences
06-Jan-2023	Turbine’s AI-powered Cancer Cell Simulations Will Be Used to Identify Novel Disease Positioning Strategies in Cancer Research UK’s Latest Biotech Partnership	Cancer Research Horizons
06-Jan-2023	Volta Medical Secures €36M in Series B Funding to Support Adoption of its AI Software for Cardiac Ablation, New CFO Introduced	Volta Medical
06-Jan-2023	Poor glycemic control in patients with type 2 diabetes can be predicted from patient information systems with the help of machine learning	University of Eastern Finland
06-Jan-2023	New Year and two new zones at Pharmapack Europe in 2024	Pharmapack Europe
06-Jan-2023	Pivotal Trial of EndeavorRx® in Adolescents with ADHD Shows Robust Improvements in Attention and Broader Clinical Outcomes	Akili, Inc.
06-Jan-2023	Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration	Transgene
06-Jan-2023	Portfolio company Twelve Bio to be acquired alongside $85 million financing of Ensoma co-led by Arix to create best-in-class engineered cell therapy platform	Arix Bioscience plc
06-Jan-2023	CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs	CureVac
06-Jan-2023	New AI editing tool to speed up editing manuscripts	Cactus Communications
06-Jan-2023	Sartorius Collaborates with RoosterBio to Advance Downstream Purification Processes for the Manufacture of Exosomes	Sartorius
06-Jan-2023	Synaffix Enters License Agreement with Amgen to Build Next Generation ADCs	Synaffix B.V.
06-Jan-2023	PharmiWeb.Jobs Welcomes Carys Mills Consulting	Carys Mills Consulting
06-Jan-2023	Genoscience Pharma announces launch of phase 2b clinical trial of ezurpimtrostat to treat hepatocarcinoma in combination with an immune checkpoint inhibitor and an antiangiogenic agent	Andrew Lloyd Associates
06-Jan-2023	HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations	HighTide Therapeutics Inc.